Tag Archives: Gbola Amusa

Chardan Capital Remains a Buy on Kodiak Sciences (KOD)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Kodiak Sciences (KOD – Research Report), with a price target of $40.00. The company’s shares closed last Monday at $29.60, close to its 52-week high

Chardan Capital Sticks to Their Buy Rating for Medicines Co (MDCO)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Medicines Co (MDCO – Research Report), with a price target of $85.00. The company’s shares closed last Monday at $68.55, close to its 52-week high

Medicines Co (MDCO) Receives a Buy from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Medicines Co (MDCO – Research Report), with a price target of $100.00. The company’s shares closed last Monday at $69.30, close to its 52-week high

Kodiak Sciences (KOD) Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Kodiak Sciences (KOD – Research Report) today and set a price target of $40.00. The company’s shares closed last Monday at $23.30, close to its 52-week high of $24.25. According

Chardan Capital Reiterates a Buy Rating on Catalyst Biosciences (CBIO)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Catalyst Biosciences (CBIO – Research Report), with a price target of $25.00. The company’s shares closed last Monday at $5.70. According to TipRanks.com, Amusa is

Chardan Capital Reiterates a Buy Rating on Provention Bio Inc (PRVB)

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Provention Bio Inc (PRVB – Research Report) today and set a price target of $18.50. The company’s shares closed last Monday at $6.37. According to TipRanks.com, Amusa is a 5-star